Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report
- PMID: 19918537
- PMCID: PMC2769307
- DOI: 10.4076/1757-1626-2-6715
Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report
Abstract
A 32-year-old male presented with diarrhoea, mucus and bleeding per rectum. On the basis of sigmoidoscopy, rectal mesalazine was commenced uneventfully, and subsequently changed to oral mesalazine due to failure to improve.He re-presented 4 days later with frequent rigors, lethargy, palpitations and was generally unwell. His condition settled with conservative management and IV antibiotics.Oral mesalazine was withheld during the first 24 hours but was recommenced on day 2. After 2 doses he developed rigors, pyrexia, tachycardia and vomiting.Oral mesalazine was discontinued thereafter and his condition progressively improved. Mesalazine has not been re-introduced.
References
-
- Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord. 2004;4(2):86–91. - PubMed
-
- Raithel M, Baenkler HW, Naegel A, Buchwald F, Schultis HW, Backhaus B, Kimpel S, Koch H, Mach K, Hahn EG, Konturek PC. Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol. 2005;56(5):89–102. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
